home / stock / rhhby / rhhby articles

RHHBY Articles, Roche Holding Ltd ADR - From 01/10/24

Stock Information
Company Name: Roche Holding Ltd ADR
Stock Symbol: RHHBY
Market: OTC
Website: roche.com
Menu
RHHBY RHHBY Quote RHHBY Short RHHBY News RHHBY Articles RHHBY Message Board
Get RHHBY Alerts

News, Short Squeeze, Breakout and More Instantly...
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference | Benzinga

In a recent revelation, CNBC’s Mad Money host Jim Cramer disclosed that the financial market values artificial intelligence (AI) technology m...
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M | Benzinga

Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug | Benzinga

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidn...

Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO | Benzinga

Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up ...
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | Benzinga

BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) announced today the completion of the previo...

Why Is Cancer Focused Poseida Therapeutics Stock Trading Higher Today? | Benzinga

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial | Benzinga

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities | Benzinga

Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chie...

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation | Benzinga

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combinati...

Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative | Benzinga

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administere...
Previous 10 Next 10